Lisdexamfetamine for Adults With Bulimia Nervosa

Status Terminated

Clinical Trial Summary

The relatively high rates of bulimia nervosa (BN) in attention-deficit/hyperactivity disorder (ADHD) cohorts suggest a relationship between the two disorders. Interestingly, case studies involving this comorbid population have observed improvements in BN symptoms when given psychostimulants for ADHD. Case studies involving BN patents without this comorbidity have also demonstrated BN symptom improvements upon psychostimulant initiation. Recent studies have also found support for the use of lisdexamfetamine dimesylate, a psychostimulant approved for ADHD, for treating moderate to severe binge eating disorder, an eating disorder akin to BN. Given these findings, there is reason to believe that psychostimulants may also be capable of treating bulimia nervosa. Ultimately, the investigators would like to conduct a large study that examines whether people who are diagnosed with BN will have fewer episodes of binge eating and purging when they are treated with the psychostimulant medication, lisdexamfetamine dimesylate (LDX). However, preliminary data would be helpful prior to undertaking such a large project. To this end, the aim of the current study is to learn more about a) enrolment rates, b) dropout rates, c) the applicability of our eligibility criteria, d) the potential effects of LDX on novel outcome measures for studying decision-making in BN, e) preliminary safety data, and f) estimates of treatment effect. Participants (n = 30) will be instructed to take LDX once daily for two months while undergoing routine testing and monitoring to gather preliminary safety and treatment data. The research will take place at the Nova Scotia Health Authority Eating Disorder Clinic.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03397446
Study type	Interventional
Source	Nova Scotia Health Authority
Contact
Status	Terminated
Phase	Phase 2
Start date	June 21, 2018
Completion date	May 19, 2020

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04174703` - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing	N/A
Terminated	`NCT04278755` - Binge Eating & Birth Control	Phase 2
Withdrawn	`NCT02978742` - Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder	N/A
Withdrawn	`NCT00988481` - Topiramate Augmentation in Bulimia Nervosa Partial Responders	Phase 4
Completed	`NCT00184301` - A Comparison Study of Treatments Given to Patients With Concurrent Eating Disorder and Personality Disorder.	N/A
Completed	`NCT00522769` - Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents	Phase 1/Phase 2
Completed	`NCT00304187` - Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa	Phase 2
Recruiting	`NCT04409457` - Self-Control in Bulimia Nervosa	N/A
Recruiting	`NCT05509257` - Naltrexone Neuroimaging in Teens With Eating Disorders	Early Phase 1
Recruiting	`NCT05862389` - Study on the Mechanism of Eating Disorder
Recruiting	`NCT05937243` - Identifying Effective Technological-based Augmentations to Enhance Outcomes From Self-help Cognitive Behavior Therapy for Binge Eating	N/A
Recruiting	`NCT05728021` - Smartphone-based Aftercare for Inpatients With Bulimia Nervosa	N/A
Completed	`NCT03781921` - The Neural Bases of Emotion Regulation in Bulimia Nervosa
Completed	`NCT02553824` - FDA Approved Medication to Reduce Binge Eating and/or Purging	Phase 1
Terminated	`NCT04041024` - Decision-making and Risk-taking in Bulimia	N/A
Completed	`NCT04265131` - Emotion Regulation in Eating Disorders: How Can Art Therapy Contribute to Treatment Outcome?	N/A
Recruiting	`NCT06431854` - Evaluation of a New Treatment Program for Adolescents With Eating Disorders: MINERVA Program	N/A
Recruiting	`NCT02960152` - Periodontal Impact of Eating Disorders (the PERIOED Study)	N/A
Completed	`NCT00916071` - Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders	N/A
Terminated	`NCT00308776` - Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa	N/A